What 300 Million Patients Makes Possible: Across Healthcare, Not Just the Drug Lifecycle

Key takeaways:

• The TriNetX LIVE™ network has crossed 300 million patients across 240+ healthcare organizations and 13,000+ sites, a single, federated source of EHR-native real-world data (RWD) supporting research and decision-making from drug discovery through post-market surveillance and beyond. 

• The network’s value extends across the healthcare ecosystem — from pharmaceutical companies and academic institutions to healthcare providers and health-tech innovators — enabling consistent, scalable access to evidence and insight. 

• The fastest growth is happening outside the U.S. Of the ~52 million patients added between April 2025 and April 2026, the majority came from EMEA, APAC, and Latin America, expanding the globally representative, decision-grade evidence base that stakeholders across the healthcare ecosystem increasingly rely on. 

This quarter, the TriNetX LIVE™ network crossed 300 million patients. It’s a milestone worth recognizing, and a milestone worth looking past, because what 300 million enables matters more than the number itself. Three things, in particular, define what has changed. 

From Discovery to Post-Market, On a Single Network

RWD has historically been fragmented. Discovery teams use one source, trial design teams use another, real-world evidence (RWE) generation a third, post-market safety yet another. Each handoff costs time, introduces methodological inconsistency, and complicates regulatory submissions that increasingly demand a coherent evidence story across stages. 

The TriNetX LIVE™ network resolves that fragmentation. The same 300M-patient network supports every stage: hypothesis generation and target identification in early discovery; protocol optimization, feasibility, and site selection in trial design; recruitment that mirrors the populations a therapy will eventually serve; and the comparative effectiveness, label expansion, and pharmacovigilance work that determines commercial trajectory and regulatory standing post-launch.  

The Data Partner for Everyone Working to Improve Patient Care

The network was built with the drug lifecycle in mind, but its impact is extending well beyond pharmaceutical R&D.  

• Academic research institutions can shorten the path from idea to peer-reviewed publication with the scale, depth, and rigor required for meaningful, defensible findings. 
• Providers can put their own data to work to improve research performance, optimize care delivery, and act with greater confidence. 
• Health-tech companies can build, train, and validate digital health tools with the scale and breadth needed for production-ready solutions. 

What unites these constituencies is not the use case. It’s the underlying need: trusted data, sourced directly; current data, not delayed extracts; clinically rich data, not billing codes; global data, not single-country snapshots. Wherever in the healthcare ecosystem someone is making decisions that affect patient outcomes, those four characteristics increasingly define the difference between a defensible decision and a guess. 

RWE is Going Global. The TriNetX LIVE™ Network has Been All Along.

Of the roughly 52 million patients added to the network April 2025-April 2026, the majority came from outside the U.S. EMEA grew patient coverage by 36% year over year. Latin America grew by 20%. APAC more than doubled, growing 110%. Thirty-four new healthcare organizations joined the network, with 19 of them in APAC alone.  

This international momentum is not incidental. Therapies developed in one country are deployed globally. Regulators are explicit about the need for evidence reflecting the populations who will receive a therapy. RWE drawn from a single country is increasingly insufficient, and the supply of credible, internationally diverse data has had to widen with that demand.  

That international diversity also matters for rare diseases and underrepresented populations where network scale plus geographic breadth turns cohorts that were once unreachable into ones researchers can now study at meaningful sample sizes. The TriNetX network’s continued strongest growth outside the U.S. is increasingly central to what makes the network valuable. 

Why Live, Not Aggregated

Scale alone isn’t the differentiator. How that scale is assembled is. Most large RWD offerings are aggregated datasets: data extracted from healthcare organizations, repackaged by an intermediary, and delivered as a one-way feed. By the time it reaches a researcher or analyst, the clinical context has been thinned, the freshness has aged, and the relationship with the source has been severed. 

The TriNetX LIVE™ network is built differently. It’s a live, bi-directional network: data flows continuously from EHR systems at participating healthcare organizations, refreshed in near real time, with full clinical context (diagnoses, labs, vitals, medications) intact, not billing proxies. Unlike competitor offerings, healthcare organizations on the network aren’t just data sources; they’re active partners who can act on what the network surfaces and shape what gets studied next. 

That architecture matters because the questions stakeholders increasingly ask, about rare populations, about real-world treatment patterns, about how care varies across geographies and care settings, can’t be answered with stale, repackaged extracts. They require data that reflect what’s happening in care now, sourced from organizations that remain part of the conversation.

The Next 300 Million

Three hundred million is a milestone, not a destination. Our roadmap calls for continued targeted growth across all four regions, deeper integration at our existing healthcare partners, and meaningful expansion in the data we bring into the network: unstructured clinical notes, oncology and genomics depth, and lower-latency data acquisition. What stays constant is what has driven the network from the start: 

• Data sourced directly from leading healthcare organizations, not intermediaries. 
• Clinical context that reflects how care actually happens.  
• The epidemiologists, data scientists, and clinical experts who help every customer translate the network into answers. 

Each of those investments expands what the next researcher, provider, or health-tech team can ask, and answer. To the partners, customers, and researchers who have built this network with us, and to those joining now: thank you. The next 300 million will go further than the first. That’s what The Global Truth Engine for Better Human Health™ is built to do, and what the next 300 million will extend. 

At TriNetX, we enable life sciences, healthcare, and academic institutions to strengthen human health — with data you can trace, evidence you can defend, and answers you can trust. Wherever you sit in the healthcare ecosystem, if your work depends on trusted, current, clinically rich data, we’d welcome the conversation. 

Find out more

Download the infographic: A Milestone in Real-World Data: 300 million patients. One live global health data network. 

Request a demo: See what 300 million patients enables.

Data is sourced in compliance with applicable privacy regulations. 

About Steve Lethbridge 

As SVP, Global Healthcare Partnerships at TriNetX, Steve leads the global teams responsible for developing and deepening TriNetX’s partnerships with healthcare providers and academic research institutions. He brings more than 25 years of experience spanning healthcare ICT, real-world data, clinical research, and consulting, and has been with TriNetX for 11 years.